Top

Osteoporosis International

Published in:

01-11-2006 | Original Article

Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis

Authors: M. C. Nevitt, P. Chen, D. P. Kiel, J.-Y. Reginster, R. K. Dore, J. R. Zanchetta, E. V. Glass, J. H. Krege

Published in: Osteoporosis International | Issue 11/2006

Abstract

Introduction

Teriparatide [rhPTH (1–34)] reduces fracture risk, and in a published meta-analysis of clinical trials, teriparatide-treated patients had reduced incidence of back pain relative to placebo or to antiresorptive drugs. The aim of this study was to evaluate back pain in teriparatide-treated versus comparator-treated patients during an interval including controlled clinical trials plus 30 months of additional follow-up.

Methods

A meta-analysis of four completed randomized, double-blinded trials of teriparatide [rhPTH (1–34)] versus comparator was performed. A multivariate Cox proportional hazards model was used to assess the heterogeneity of results and to estimate the relative risk of back pain.

Results

Patients in the pooled teriparatide group had reduced risk for any back pain [relative risk, 0.73 (95% CI, 0.61–0.87)], moderate or severe back pain [0.72 (0.58–0.89)], and severe back pain [0.39 (0.25–0.61)] compared with pooled controls, from initiation of the study drug through the end of follow-up. Sensitivity analysis showed that the results were robust to the removal of each individual trial from the meta-analysis. Separate meta-analyses comparing teriparatide versus placebo or antiresorptive drugs gave similar results.

Conclusions

Teriparatide-treated patients had a reduced incidence of back pain versus those receiving a comparator during an observation encompassing clinical trials plus 30 months of posttreatment observation.

Riggs BL, Melton LJ III (1995) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17(5 Suppl):505S–511SPubMedCrossRef

Nevitt MC, Ettinger B, Black DM et al (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128(10):793–800PubMed

Cooper C, Atkinson EJ, O'Fallon WM (1992) Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989. J Bone Miner Res 7:221–227PubMedCrossRef

Fink HA, Milavetz DL, Palermo L et al (2005) What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res 20:1216–1222PubMedCrossRef

Silverman SL, Piziak VK, Chen P et al (2005) Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. J Rheumatol 32(12):2405–2409PubMed

Genant HK, Halse J, Briney WG et al (2005) The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin 21(7):1027–1034PubMedCrossRef

Gold DT (1996) The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 18(3 Suppl):185S–189SPubMedCrossRef

Edmond SL, Kiel DP, Samelson EJ et al (2005) Vertebral deformity, back symptoms, and functional limitations among older women: the Framingham study. Osteoporos Int 6(9):1086–1095

Ismail AA, Cooper C, Felsenberg D et al (1999) Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European vertebral osteoporosis study group. Osteoporos Int 9(3):206–213PubMedCrossRef

10.

Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434–1441PubMedCrossRef

11.

Lindsay R, Scheele WH, Neer R et al (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164(18):2024–2030PubMedCrossRef

12.

Miller PD, Shergy WJ, Body JJ et al (2005) Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatol 32(8):1556–1562PubMed

13.

Nevitt MC, Chen P, Dore RK et al (2006) Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 17(2):273–280PubMedCrossRef

14.

Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18(1):9–17PubMedCrossRef

15.

Body JJ, Gaich GA, Scheele WH et al (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87(10):4528–4535PubMedCrossRef

16.

Ste-Marie LG, Schwartz SL, Hossain AM et al (2006) Effect of teriparatide [rh parathyroid hormone (1–34)] on bone density when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res 21(2):283–291PubMedCrossRef

17.

Kaufman JM, Orwoll E, Goemaere S et al (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16(5):510–516PubMedCrossRef

18.

Gold DT (1996) The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 18(suppl 3):185–189CrossRef

19.

Cooper C (1993) Epidemiology and public health impact of osteoporosis. Clin Rheumatol 7:459–477

20.

Andersson GB (1999) Epidemiological features of chronic low-back pain. Lancet 354:581–585PubMedCrossRef

Title: Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis
Authors: M. C. Nevitt
P. Chen
D. P. Kiel
J.-Y. Reginster
R. K. Dore
J. R. Zanchetta
E. V. Glass
J. H. Krege
Publication date: 01-11-2006
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 11/2006
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-006-0177-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis

Abstract

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2006

Can you diagnose for vertebral fracture correctly by plain X-ray?

Former college artistic gymnasts maintain higher BMD: a nine-year follow-up

Association of PLXNA2 polymorphisms with vertebral fracture risk and bone mineral density in postmenopausal Korean population

A 19-week exercise program for people with chronic stroke enhances bone geometry at the tibia: a peripheral quantitative computed tomography study

Bone fragility in men - where are we?

Minimum sample size requirements for bone density precision assessment produce inconsistency in clinical monitoring